Moffitt Cancer Center Launches Immunotherapy Contract Research Organization

Moffitt Cancer Center Launches Immunotherapy Contract Research Organization

The new organization will provide end-to-end services for pharmaceutical and biotech companies seeking to accelerate immuno-oncology and cell therapy research.

Moffitt Cancer Center
Oct 03, 2019, 10:01 ET

TAMPA, Fla., Oct. 3, 2019 /PRNewswire/ — Moffitt Cancer Center announced today the launch of a first-of-its-kind contract research organization (CRO) focused on accelerating immunotherapy research. The subsidiary will provide a one-stop-shop for pharmaceutical and biotech companies to accelerate their immuno-oncology and cell therapy research through collaborative clinical trial support and administration.

Read More

The Latest News & Events


Take Advantage of OncoBay’s Innovative Approach


Submit a Request for Proposal

Submit Proposal

OncoBay is now Kapadi


Once three entities – OncoBay Clinical, Clinscience, and Exom Group s.r.l – now we stand as one, bringing forth a symphony of expertise and seamless operations. To celebrate our unity, we re-brand under the banner of Kapadi, and embark on a new chapter of exceptional service in oncology clinical research.

Kapadi is not just a name; it's a testament to our fusion. It signifies the our standing as a global CRO powerhouse committed to accelerating groundbreaking cancer therapies that uplift patients worldwide. From conceptualizing studies, navigating regulations, and analyzing data, we provide a comprehensive array of services designed to empower your oncology clinical trials.




This pop-up will auto-close in 10 seconds.

This will close in 5 seconds